NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Clearmind Medicine Inc. (CMND) Stock Analysis

Clearmind Medicine Inc. (CMND) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CMND

$1.16

−$0.54 (−31.76%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CMND with… →

CMND Key Statistics

As of Sep 4, 2026
Trading
Open
$1.50
Previous Close
$1.70
Day's Range
1.16–1.56
52-Week Range
1.16–524.00
Volume
15.42M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.14
Valuation
Market Cap
$1.72M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−122.08
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$3.86M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
1.49M
1-Year Return
−99.72%
Dividend and dates
Avg Volume
501.28K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CMND Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−93.59%
2025−96.72%
2024−50.89%
2023−97.04%
2022 (partial year)−46.44%

As of September 4, 2026.

CMND Revenue and Earnings by Fiscal Year

FY ends October
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$3.86M—
2024$0.00−$5.25M—
2023$0.00−$8.62M—
2022$0.00−$6.89M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$5.67M−$3.86M—
2024$0.00—−$5.74M−$5.25M—
2023$0.00—−$6.30M−$8.62M—
2022$0.00—−$6.25M−$6.89M—

Annual figures as reported, in the company's reporting currency. As of October 31, 2025.

CMND Valuation vs Biotechnology Median

Median of 656 stocks
MetricCMNDBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Clearmind Medicine Inc. (CMND) is capitalised at $1.72M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry.

CMND last closed at $1.16 on September 4, 2026. That is −$0.54 (−31.76%) against the previous close. The 52-week range on file runs from $1.16 to $524.00.

Financial Health

In fiscal 2025, Clearmind Medicine Inc. reported revenue of $0.00. The same year closed with a net loss of $3.86M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −122.08.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The reported beta is −1.14. Annualized volatility over the trailing 3 years is 137.73%. The trailing one-year price return is −99.72%. Measured over 3 years, that is −93.79% a year compounded.

Growth & Income

No dividend is on file for CMND.

So far in 2026 the price is −93.59%. The strongest complete calendar year on file is 2024 at −50.89%; the weakest is 2023 at −97.04%. Of the 3 complete calendar years on file, 0 finished higher.

Peer Comparison

Clearmind Medicine Inc. (CMND) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Clearmind Medicine Inc. CMND $1.72M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Clearmind Medicine Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Clearmind Medicine Inc.

Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.

Visit website →